Trial · NCT00524030
Results by group26
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 26
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants in the Pregabalin 600 mg/Day Treatment Group Discontinuing the Study Due to at Least 1 Pre-Defined Seizure Exit Criteria | Pregabalin 600 mg/Day | 31.9 | 95% Confidence Interval 20.7 to 43.1 | Percentage of Participants | |
| Percentage of Participants in the Pregabalin 150 mg/Day Treatment Group Discontinuing the Study Due to at Least 1 Pre-Defined Seizure Exit Criteria | Pregabalin 150 mg/Day | 37.7 | 95% Confidence Interval 15.4 to 60 | Percentage of Participants | |
| Percentage of Participants Completing 20 Weeks of Double-Blind Treatment | Pregabalin 150 mg/Day | 53.6 | Percentage of Participants | ||
| Percentage of Participants Completing 20 Weeks of Double-Blind Treatment | Pregabalin 600 mg/Day | 58.3 | Percentage of Participants | ||
| Percentage of Participants Who Met Protocol-Specified Exit Events | Pregabalin 150 mg/Day | Status Epilepticus | 0 | Percentage of Participants | |
| Percentage of Participants Who Met Protocol-Specified Exit Events | Pregabalin 600 mg/Day | Status Epilepticus | 1.0 | Percentage of Participants | |
| Percentage of Participants Who Met Protocol-Specified Exit Events | Pregabalin 150 mg/Day | SGTC Seizure (not experienced in previous 2 years) | 0 | Percentage of Participants | |
| Percentage of Participants Who Met Protocol-Specified Exit Events | Pregabalin 600 mg/Day | SGTC Seizure (not experienced in previous 2 years) | 2.9 | Percentage of Participants | |
| Percentage of Participants Who Met Protocol-Specified Exit Events | Pregabalin 150 mg/Day | 28-Day Seizure Rate >2 times Max Baseline Rate | 13.0 | Percentage of Participants | |
| Percentage of Participants Who Met Protocol-Specified Exit Events | Pregabalin 600 mg/Day | 28-Day Seizure Rate >2 times Max Baseline Rate | 10.8 | Percentage of Participants | |
| Percentage of Participants Who Met Protocol-Specified Exit Events | Pregabalin 150 mg/Day | 2-Day Seizure Rate >2 times Max Baseline Rate | 13.0 | Percentage of Participants | |
| Percentage of Participants Who Met Protocol-Specified Exit Events | Pregabalin 600 mg/Day | 2-Day Seizure Rate >2 times Max Baseline Rate | 7.8 | Percentage of Participants | |
| Percentage of Participants Who Met Protocol-Specified Exit Events | Pregabalin 150 mg/Day | Increased Frequency/Intensity of Seizure Activity | 17.4 | Percentage of Participants | |
| Percentage of Participants Who Met Protocol-Specified Exit Events | Pregabalin 600 mg/Day | Increased Frequency/Intensity of Seizure Activity | 14.7 | Percentage of Participants | |
| Percentage of Participants Who Met Protocol-Specified Exit Events | Pregabalin 150 mg/Day | Total | 39.1 | Percentage of Participants | |
| Percentage of Participants Who Met Protocol-Specified Exit Events | Pregabalin 600 mg/Day | Total | 28.4 | Percentage of Participants | |
| Mean Time on Pregabalin Monotherapy | Pregabalin 150 mg/Day | 73.8 | Standard Deviation 30.15 | Days | |
| Mean Time on Pregabalin Monotherapy | Pregabalin 600 mg/Day | 78.0 | Standard Deviation 28.24 | Days | |
| Percentage of Seizure-Free Participants by Study Phase | Pregabalin 150 mg/Day | Last 28 Days of Monotherapy (Days 112-140) | 17.9 | Percentage of Participants | |
| Percentage of Seizure-Free Participants by Study Phase | Pregabalin 600 mg/Day | Last 28 Days of Monotherapy (Days 112-140) | 12.5 | Percentage of Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00524030/results